Patents Assigned to SAVIRA PHARMACEUTICALS GMBH
  • Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 9827244
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: November 28, 2017
    Assignees: F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH, European Molecular Biology Laboratory
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • Substituted 1,5-naphthyridines as endonuclease inhibitors
    Patent number: 9505758
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: November 29, 2016
    Assignees: Savira pharmaceuticals GmbH, F. Hoffman-La Roche AG, European Molecular Biology Laboratory
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Publication number: 20160297763
    Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Applicants: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)
    Inventors: Dirk CLASSEN-HOUBEN, Andrea WOLKERSTORFER, Oliver SZOLAR, Mark SMITH, Sung-Sau SO, Stephen CUSACK, Thierry LANGER, Bruno GIETHLEN, Christophe MORICE, Céline MICHAUT-SIMON, Chloe ZUBIETA
  • 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 9434745
    Abstract: The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: September 6, 2016
    Assignees: Savira pharmaceuticals GmbH, F. Hoffmann-La Roche AG, European Molecular Biology Laboratory
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Stephen Cusack, Thibault Sauvaitre, Céline Simon, Christophe Morice, Bruno Giethlen, Thierry Langer, Mark Smith, Sung-Sau So, Dirk Classen-Houben, Helmut Buschmann
  • Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 9359351
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 7, 2016
    Assignees: F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH, European Molecular Biology Laboratory
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease
    Patent number: 9199987
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 1, 2015
    Assignees: Savira pharmaceuticals GmbH, European Molecular Biology Laboratory, F. Hoffmann-La Roche AG
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 9045486
    Abstract: The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: June 2, 2015
    Assignees: Savira pharmaceuticals GmbH, European Molecular Biology Laboratory, F. Hoffman-La Roche AG
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri, Zhuming Zhang
  • Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease
    Patent number: 8952039
    Abstract: The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: February 10, 2015
    Assignees: European Molecular Biology Laboratory, F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley
  • Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 8921388
    Abstract: The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 30, 2014
    Assignees: European Molecular Biology Laboratory, F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH
    Inventors: Helmut Buschmann, Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Stephen Cusack, Mark Smith, Sung-Sau So
  • Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Publication number: 20140038990
    Abstract: The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 6, 2014
    Applicants: SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY, F. HOFFMANN-LA ROCHE AG
    Inventors: Helmut BUSCHMANN, Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Stephen CUSACK, Mark SMITH, Sung-Sau SO
  • Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Publication number: 20130102600
    Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 18, 2012
    Publication date: April 25, 2013
    Applicants: F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
    Inventors: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT
  • Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Publication number: 20130102601
    Abstract: The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 18, 2012
    Publication date: April 25, 2013
    Applicants: F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
    Inventors: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT